The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | KEYNOTE-811: final OS results of pembrolizumab, trastuzumab and chemotherapy in G/GEJ
Yelena Janjigian, MD, Memorial Sloan Kettering Cancer Center, New York, NY, comments on the final overall survival (OS) analysis of the Phase III KEYNOTE-811 study (NCT03615326), which assessed first-line pembrolizumab with trastuzumab and chemotherapy in patients with unresectable, HER2+ metastatic gastric or gastroesophageal junction cancer (mG/GEJ). The combination significantly improved OS and progression-free survival (PFS) compared to placebo plus trastuzumab and chemotherapy. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
